TARGET: a phase I/II open-label multicentre study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion positive glioma

Picca, A., Di Stefano, A. L., Savatovsky, J., Ducray, F., Chinot, O., Moyal, E. C.-J., Augereau, P., Le Rhun, E., Schmitt, Y., Rousseaux, N., Yepnang, A. M. M., Estellat, C., Charbonneau, F., Letourneur, Q., Branger, D. F., Meyronet, D., Fardeau, C., Mokhtari, K., Bielle, F., … Sanson, M. (2024). TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae068
Authors:
Alberto Pïcca
Anna Luisa Di Stefano
Julien Savatovsky
François Ducray
Olivier Chinot
E. Cohen-Jonathan Moyal
Paule Augereau
Émilie Le Rhun
Yohann Schmitt
Nabila Rousseaux
Ariane Murielle Mbekwe Yepnang
Candice Estellat
F. Charbonneau
Quentin Letourneur
Dominique Figarella Branger
David Meyronet
Christine Fardeau
Karima Mokhtari
Franck Bielle
Antonio Iavarone
Marc Sanson
Affiliated Authors:
Antonio Iavarone
Columbia Affiliation:
Subjects:
Author Keywords:
clinical trial
fexagratinib
fgfr inhibitor
fgfr3-tacc3
glioblastoma
glioma
fgfr3–tacc3
Publication Type:
Article
Unique ID:
10.1093/noajnl/vdae068
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: